Scholars Central

EditorialPublished 4 Jan 2018

Epigenetic altering drugs as immunotherapies.

Authors: Rasika M. Samarasinghe

Journal of Cancer Immunology & Therapy

Volume 1 · Issue 1 · Pages 24–25

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Despite of our increasing understanding of the molecular, genetic and phenotypic progression of cancers, treatments that can effectively combat most malignant cancers remain suboptimal [1]. A major challenge with current therapies is that they focus on existing genetic abnormalities but usually become ineffectual due to cancers becoming resistant or not expressing the specific mutation. Advances in high-throughput DNA sequencing of various cancers before and after treatment and after recurrence, has provided researchers with comprehensive collections of driver and passenger mutations that can be utilised to develop novel therapies. However, these sequencing techniques can be costly and usually results in the output of large and complex datasets that require specialised knowledge of different computational analysis [2].

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Cancer Immunology & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Cancer Immunology & Therapy
  • SubjectOncology & Cancer
  • SubjectImmunology & Microbiology
  • BylineArticles whose byline prints “Rasika M. Samarasinghe”